<DOC>
	<DOCNO>NCT00651599</DOCNO>
	<brief_summary>Study demonstrate therapeutic efficacy AngeliqÂ® good placebo Korean postmenopausal woman hot flush climacteric symptom . Safety tolerability Angeliq .</brief_summary>
	<brief_title>Treatment Vasomotor Symptoms Korean Post Menopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Drospirenone ethinyl estradiol combination</mesh_term>
	<criteria>Postmenopausal Korean woman suffer hot flush Standard exclusion criterion HRT clinical trial obey , include current history hormone dependent malignant disease , thromboembolic disorder , abnormal cervical smear , undiagnosed vaginal bleeding .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Vasomotor symptom</keyword>
	<keyword>Vasomotor System</keyword>
</DOC>